Suppression of RhoA or FAK selectively induced death in mutant Kras/Ink4a-Arf–deficient NSCLC cells, and pharmacologic inhibition of FAK caused regression of high-grade NSCLC in mutant Kras/Cdkn2a-null mice [16]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.